-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 18, 2021, Oyster Point Pharma announced that the US FDA has approved Tyrvaya (varenicline) nasal spray for the treatment of dry eye
Dry eye is a chronic disease that can cause persistent stinging, burning sensation, sensitivity to light, blurred vision, and eye fatigue
Unlike other eye drops, Tyrvaya nasal spray is a highly selective cholinergic agonist, delivered as an aqueous nasal spray twice a day
Image source: Oyster Point's official website
This approval is based on positive data from a series of clinical trials that evaluated Tyrvaya nasal spray in more than 1,000 patients with mild/moderate/severe dry eye
Reference materials:
[1] Oyster Point Pharma Announces FDA Approval of Tyrvaya™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease.
(The original text has been deleted)